

# Carlos A Morillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6577413/publications.pdf>

Version: 2024-02-01

73  
papers

10,753  
citations

126907

33  
h-index

88630

70  
g-index

77  
all docs

77  
docs citations

77  
times ranked

10139  
citing authors

#	ARTICLE	IF	CITATIONS
1	Approaches to Catheter Ablation for Persistent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 372, 1812-1822.	27.0	1,725
2	Cryptogenic Stroke and Underlying Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2014, 370, 2478-2486.	27.0	1,694
3	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	2.2	1,200
4	2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. <i>Heart Rhythm</i> , 2015, 12, e41-e63.	0.7	694
5	Evaluation and Treatment of Chagas Disease in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2171.	7.4	654
6	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
7	Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 692.	7.4	533
8	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	2.2	428
9	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 138, e169-e209.	1.6	315
10	Discerning the Incidence of Symptomatic and Asymptomatic Episodes of Atrial Fibrillation Before and After Catheter Ablation (DISCERN AF). <i>JAMA Internal Medicine</i> , 2013, 173, 149.	5.1	267
11	Prevention of Syncope Trial (POST). <i>Circulation</i> , 2006, 113, 1164-1170.	1.6	256
12	Atrial fibrillation: the current epidemic. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 195-203.	0.2	208
13	2015 HRS/EHRA/APHS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Heart Rhythm</i> , 2016, 13, e50-e86.	0.7	197
14	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
15	Predictors for atrial fibrillation detection after cryptogenic stroke. <i>Neurology</i> , 2016, 86, 261-269.	1.1	153
16	Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003333.	4.8	149
17	American Trypanosomiasis (Chagas Disease). <i>Infectious Disease Clinics of North America</i> , 2019, 33, 119-134.	5.1	145
18	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021.	2.2	125

#	ARTICLE	IF	CITATIONS
19	Fludrocortisone for the Prevention of Vasovagal Syncope. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1-9.	2.8	116
20	Dual-Chamber Pacing With Closed-Loop Stimulation in Recurrent Reflex Vasovagal Syncope. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1720-1728.	2.8	102
21	Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. <i>European Heart Journal</i> , 2016, 37, 1493-1498.	2.2	96
22	WHF IASC Roadmap on Chagas Disease. <i>Global Heart</i> , 2020, 15, 26.	2.3	75
23	Age-Dependent Effect of $\beta$ -Blockers in Preventing Vasovagal Syncope. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 920-926.	4.8	68
24	Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting <i>Trypanosoma cruzi</i> Discrete Typing Units (A BENEFIT TRIAL Sub-Study). <i>PLoS ONE</i> , 2014, 9, e91154.	2.5	65
25	Atrial Fibrillation Detected After Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. <i>Stroke</i> , 2022, 53, STROKEAHA121034777.	2.0	57
26	Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006567.	3.0	53
27	Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: A substudy of the STAR AF II trial. <i>Heart Rhythm</i> , 2017, 14, 476-483.	0.7	51
28	Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 3-25.	2.8	50
29	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. <i>American Heart Journal</i> , 2013, 165, 558-566.	2.7	44
30	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 170-180.	3.2	44
31	COVID-19: Implications for People with Chagas Disease. <i>Global Heart</i> , 2020, 15, 69.	2.3	39
32	Midodrine for the Prevention of Vasovagal Syncope. <i>Annals of Internal Medicine</i> , 2021, 174, 1349-1356.	3.9	37
33	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. <i>Global Heart</i> , 2017, 12, 273.	2.3	35
34	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Journal of Arrhythmia</i> , 2016, 32, 1-28.	1.2	34
35	Low-blood pressure phenotype underpins the tendency to reflex syncope. <i>Journal of Hypertension</i> , 2021, 39, 1319-1325.	0.5	34
36	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 389-395.	1.7	33

#	ARTICLE	IF	CITATIONS
37	Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 227, 577-582.	1.7	24
38	Association Between Quality of Life and Procedural Outcome After Catheter Ablation for Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e2025473.	5.9	18
39	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 113-120.	0.3	18
40	Cardiovascular profile in postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome type III. <i>Clinical Autonomic Research</i> , 2017, 27, 113-116.	2.5	13
41	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. <i>Clinical Cardiology</i> , 2018, 41, 440-449.	1.8	12
42	Implantable cardioverter-defibrillator in Chagas heart disease: A systematic review and meta-analysis of observational studies. <i>International Journal of Cardiology</i> , 2018, 267, 88-93.	1.7	11
43	Clinician needs and perceptions about cardioneuroablation for recurrent vasovagal syncope: An international clinician survey. <i>Heart Rhythm</i> , 2021, 18, 2160-2166.	0.7	11
44	Current management of syncope: Treatment alternatives. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 371-383.	0.9	10
45	Syncope and Driving. <i>Cardiology Clinics</i> , 2015, 33, 465-471.	2.2	10
46	Impact of dual-chamber pacing with closed loop stimulation on quality of life in patients with recurrent reflex vasovagal syncope: results of the SPAIN study. <i>Europace</i> , 2020, 22, 314-319.	1.7	9
47	Association of Cardiovascular Disease and Sleep Apnea at Different Altitudes. <i>High Altitude Medicine and Biology</i> , 2016, 17, 336-341.	0.9	8
48	Circulating <i>Trypanosoma cruzi</i> load and major cardiovascular outcomes in patients with chronic Chagas cardiomyopathy: a prospective cohort study. <i>Tropical Medicine and International Health</i> , 2020, 25, 1534-1541.	2.3	8
49	Cardioneuroablation for vasovagal syncope and atrioventricular block: A step-by-step guide. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 2205-2212.	1.7	8
50	The Effect of Sham Feeding on Neurocardiac Regulation in Healthy Human Volunteers. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 721-726.	1.7	7
51	Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190477.	0.9	7
52	Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 812.	6.1	6
53	Measuring Success in Ablation of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006582.	4.8	6
54	Lack of Equity in the Cardiology Physician Workforce: A Narrative Review and Analysis of the Literature. <i>CJC Open</i> , 2021, 3, S180-S186.	1.5	6

#	ARTICLE	IF	CITATIONS
55	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS ONE, 2021, 16, e0258622.	2.5	6
56	Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?. Current Cardiology Reports, 2016, 18, 71.	2.9	5
57	Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10-year experience in a single center. Transplant Infectious Disease, 2021, 23, e13549.	1.7	4
58	Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. Global Heart, 2020, 15, 36.	2.3	4
59	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). Open Forum Infectious Diseases, 2021, 8, ofab513.	0.9	4
60	Longitudinal strain by speckle tracking and echocardiographic parameters as predictors of adverse cardiovascular outcomes in chronic Chagas cardiomyopathy. International Journal of Cardiovascular Imaging, 2022, 38, 1245-1255.	1.5	4
61	Effect of Postablation Monitoring Strategy on Long-Term Outcome for Catheter Ablation of Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008682.	4.8	3
62	Completeness of Linear or Fractionated Electrogram Ablation in Addition to Pulmonary Vein Isolation on Ablation Outcome. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010146.	4.8	3
63	Implantable Cardioverter Defibrillator mHealth App for Physician Referrals and eHealth Education: ICD-TEACH Pilot Study. JMIR Cardio, 2018, 2, e10499.	1.7	3
64	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace, 2021, 23, 65-72.	1.7	2
65	Incidence of Concurrent Atrial Fibrillation in Patients Who Present With Atrial Tachycardia and Atrial Flutter Postablation for Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008683.	4.8	2
66	Sudden cardiac death: improving our pathological diagnosis—are we there yet?. Europace, 2014, 16, 785-786.	1.7	1
67	Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 751415.	2.4	1
68	Atrial fibrillation after transcatheter patent foramen ovale closure: To measure is to know. Heart Rhythm, 2022, 19, 1421-1422.	0.7	1
69	Nitroglycerine in HUTT - An explosion in Our Understanding of Unexplained Syncope?. Indian Pacing and Electrophysiology Journal, 2013, 13, 200-202.	0.6	0
70	Cardiovascular testing in patients with postural tachycardia syndrome and Ehlers-Danlos type III: authors' response. Clinical Autonomic Research, 2017, 27, 119-120.	2.5	0
71	Atrial fibrillation ablation long-term outcomes: is there light at the end of the tunnel?. Europace, 2018, 20, 1065-1066.	1.7	0
72	Measuring the QT interval on the go. Cardiology Journal, 2021, 28, 358-359.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Symptom reduction in initial orthostatic hypotension: Time to get physical!. Heart Rhythm, 2022, 19, 611-612.	0.7	0